GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis
Sign Up to like & getrecommendations! Published in 2017 at "BMJ Case Reports"
DOI: 10.1136/bcr-2017-221078
Abstract: Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC). Tofacitinib inhibits cytokine signalling through blockade of JAK1, JAK2, JAK3 and tyrosine kinase… read more here.
Keywords: inhibitor; two patients; gsk2586184; jak1 selective ... See more keywords
Abstract 979: Discovery of the JAK1 selective kinase inhibitor AZD4205
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-979
Abstract: Janus kinases are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are critical in cytokine signalling, with constitutive activation of JAK/STAT pathways associated with a wide variety of malignancies.… read more here.
Keywords: kinase; kinase inhibitor; jak1 selective; selective kinase ... See more keywords